Bevacizumab in Ovarian Cancer

Introduction: Ovarian cancer is a serious gynecological malignancy associated with high mortality and frequent recurrence.

Background: Advanced ovarian cancer remains challenging to treat due to disease progression, chemotherapy resistance, and recurrence.

Study Objective: To evaluate the efficacy and safety of bevacizumab in ovarian cancer through a systematic review.

Mechanism of Action: Examine how bevacizumab inhibits VEGF, reducing tumor angiogenesis and blood supply.

Efficacy: Assess its effectiveness in improving progression-free survival and overall treatment outcomes.

Safety and Adverse Effects: Evaluate adverse effects, including hypertension, proteinuria, bleeding, and gastrointestinal complications.

Dosage and Administration: Review recommended dosage, administration methods, and treatment duration.

Comparative Analysis: Compare bevacizumab with standard chemotherapy and other treatment approaches.

Clinical Outcomes: Assess improvements in disease control, survival rates, and recurrence prevention.

Challenges and Limitations: Examine treatment resistance, adverse effects, high treatment costs, and limited long-term evidence.

Conclusion: Understanding the efficacy and safety of bevacizumab is essential for determining its role in advanced ovarian cancer treatment.